title: Triglycerides: how much credit do they deserve?
abstract: In the modern era of statin therapy, major advances have been made in treating coronary heart disease. However, despite intensive treatment with statin therapy, residual cardiovascular risk persists and has been attributed to the persistence of atherogenic dyslipidemia and, in part, elevated triglycerides (TGs). In this review, the authors focus on the mechanism of elevated TGs and provide a discussion of the challenges of measuring TGs as a biomarker, its role in the pathogenesis of atherosclerotic heart disease, and results of several recent studies that have elucidated the relationship between TGs and cardiovascular morbidity and mortality.
authors.affiliation: TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham & Women's Hospital, Boston, MA 02115, USA. pkohli@partners.org
authors.forename: Payal
authors.initials: P
authors.lastname: Kohli
authors.forename: Christopher P
authors.initials: CP
authors.lastname: Cannon
mesh_terms: D050197:Atherosclerosis / Q000188:drug therapy / Q000209:etiology / Q000378:metabolism*; D015415:Biomarkers; D002986:Clinical Trials as Topic; D003324:Coronary Artery Disease / Q000209:etiology / Q000378:metabolism / Q000401:mortality / Q000517:prevention & control*; D050171:Dyslipidemias / Q000150:complications / Q000188:drug therapy / Q000453:epidemiology / Q000378:metabolism; D006801:Humans; D000960:Hypolipidemic Agents / Q000627:therapeutic use*; D015994:Incidence; D050356:Lipid Metabolism / Q000187:drug effects*; D009026:Mortality; D015999:Multivariate Analysis; D011237:Predictive Value of Tests; D012307:Risk Factors; D040242:Risk Reduction Behavior; D014280:Triglycerides / Q000378:metabolism*
chemical_list: D015415:Biomarkers; D000960:Hypolipidemic Agents; D014280:Triglycerides